- Previous Close
0.1830 - Open
0.1880 - Bid 0.1880 x --
- Ask 0.2140 x --
- Day's Range
0.1880 - 0.2140 - 52 Week Range
0.1360 - 0.4160 - Volume
345 - Avg. Volume
15 - Market Cap (intraday)
13.826M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1660 - Earnings Date May 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Solasia Pharma K.K., a specialty pharmaceutical company, develops, imports/exports, and markets pharmaceutical products and medical devices, etc. in Japan. It offers SP-01 Sancuso, a transdermal delivery system that delivers the anti-emetic and granisetron into the patients bloodstream to patients receiving chemotherapy; and SP-02 Darinaparsin, a mitochondrial-targeted agent for the treatment of various hematologic and solid cancers, as well as SP-03 episil, an oral liquid for the treatment of pain associated with oral mucositis. The company was founded in 2006 and is based in Tokyo, Japan.
www.solasia.co.jp16
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 9SO.SG
View MorePerformance Overview: 9SO.SG
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9SO.SG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9SO.SG
View MoreValuation Measures
Market Cap
43.23M
Enterprise Value
37.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.58
Price/Book (mrq)
5.57
Enterprise Value/Revenue
19.36
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-94.61%
Return on Assets (ttm)
-7.38%
Return on Equity (ttm)
-21.40%
Revenue (ttm)
4.52M
Net Income Avi to Common (ttm)
-6.87M
Diluted EPS (ttm)
-0.1660
Balance Sheet and Cash Flow
Total Cash (mrq)
9.36M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.56M